The Foundation for Women’s Cancer and TESARO Announce 2nd Year of Partnership Supporting the National Race to End Women’s Cancer
October 18, 2017 08:00 ET
|
TESARO, Inc.
CHICAGO and WALTHAM, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) -- The Foundation for Women’s Cancer (FWC), the official foundation of the Society of Gynecologic Oncology, and TESARO, Inc. (NASDAQ:TSRO),...
TESARO Expands Our Way Forward Program for the Ovarian Cancer Community and Partners With Olympic Gymnast Shannon Miller
September 28, 2017 16:30 ET
|
TESARO, Inc.
WALTHAM, Mass., Sept. 28, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, announced today the availability of a number of new support resources...
TESARO Receives Positive CHMP Opinion for ZEJULA®
September 15, 2017 07:45 ET
|
TESARO, Inc.
ZUG, Switzerland, Sept. 15, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee...
TESARO Summarizes ZEJULA and TSR-042 Data Presented at the 2017 ESMO Annual Meeting
September 11, 2017 08:00 ET
|
TESARO, Inc.
MADRID, Spain, Sept. 11, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today provided a summary of ZEJULA and TSR-042, an anti-PD-1 antibody,...
TESARO Announces Nine Data Presentations at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting
August 25, 2017 08:01 ET
|
TESARO, Inc.
WALTHAM, Mass., Aug. 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that data from nine abstracts will be presented at the...
TESARO Announces Participation at Four Investor Conferences
August 23, 2017 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., Aug. 23, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in four upcoming investor...
TESARO Announces Second-Quarter 2017 Operating Results
August 08, 2017 16:05 ET
|
TESARO, Inc.
ZEJULA is the most prescribed PARP inhibitor in U.S.; Q2 net sales totaled $26 million in first quarter of availabilityRecently opened European niraparib EAP has enrolled 200 patientsVARUBY oral...
TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan
July 27, 2017 07:00 ET
|
TESARO, Inc.
– Takeda’s Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia – TESARO to Receive $100 Million Upfront...
TESARO to Announce Second-Quarter 2017 Financial Results on August 8, 2017
July 25, 2017 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., July 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its second-quarter 2017 financial results on Tuesday, August 8, 2017, after the close of the U.S. financial...
TESARO Joins OCRFA as Presenting Sponsor of the 2017 Ovarian Cancer National Conference
June 29, 2017 09:00 ET
|
TESARO, Inc.
WALTHAM, Mass., June 29, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to support the Ovarian Cancer Research Fund Alliance (OCRFA) as...